Literature DB >> 12051880

Uptake of a cholesterol-rich emulsion by breast cancer.

Silvia R Graziani1, Fernando A F Igreja, Roberto Hegg, Claudio Meneghetti, Laura I Brandizzi, Renato Barboza, Rosângela F Amâncio, José A Pinotti, Raul C Maranhão.   

Abstract

OBJECTIVE: Overexpression of low-density lipoprotein (LDL) receptors occurs in several cancer cell lines and offers a unique strategy for drug targeting by using LDL as vehicle. However, the native lipoprotein is difficult to obtain and handle. Previously, we showed that a lipidic emulsion (LDE) similar to the lipid structure of native LDL may bind to LDL receptors and be taken up by acute myelocytic leukemia cells. We also showed that LDE can also concentrate in ovarian cancer tissue. In this study, we tested whether LDE is taken up by breast carcinoma.
METHODS: LDE labeled with (99m)Tc was injected into 18 breast cancer patients, and nuclear medicine images of the tumor and metastatic sites were acquired. Subsequently, LDE labeled with [3H]cholesteryl oleate was intravenously injected into 14 breast cancer patients 24-30 h before total mastectomy procedure. Fragments of normal and of breast cancer tissue excised during surgery were lipid extracted with chloroform/methanol and their radioactivity was measured in a scintillation solution.
RESULTS: (99m)Tc-LDE images of the primary tumor and of metastasis sites were obtained in all 18 breast cancer patients. As directly measured in the tumor and in the normal mammary tissue, the amount of the emulsion radioactive label in the tumor was 4.5 times greater than in the normal tissue (range 1.2- to 8.8-fold).
CONCLUSION: LDE concentrates much more in malignant breast tumor tissue than in the normal tissue. Thus it has potential to carry drugs or radionuclides directed against mammary carcinoma cells for diagnostic or therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051880     DOI: 10.1006/gyno.2002.6654

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

1.  Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.

Authors:  Silvia R Graziani; Carolina G Vital; Aleksandra T Morikawa; Brigitte M Van Eyll; Hezio J Fernandes Junior; Roberto Kalil Filho; Raul C Maranhão
Journal:  Med Oncol       Date:  2017-07-29       Impact factor: 3.064

2.  Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.

Authors:  Ian R Corbin; Hui Li; Juan Chen; Sissel Lund-Katz; Rong Zhou; Jerry D Glickson; Gang Zheng
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

Review 3.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

4.  Tissue Uptake Mechanisms Involved in the Clearance of Non-Protein Nanoparticles that Mimic LDL Composition: A Study with Knockout and Transgenic Mice.

Authors:  Elaine N Daminelli; Panagiotis Fotakis; Carlos H Mesquita; Raul C Maranhão; Vassilis I Zannis
Journal:  Lipids       Date:  2017-11-01       Impact factor: 1.880

5.  Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model.

Authors:  N Alikhani; R D Ferguson; R Novosyadlyy; E J Gallagher; E J Scheinman; S Yakar; D LeRoith
Journal:  Oncogene       Date:  2012-04-02       Impact factor: 9.867

6.  Modification of composition of a nanoemulsion with different cholesteryl ester molecular species: effects on stability, peroxidation, and cell uptake.

Authors:  Cristina P Almeida; Carolina G Vital; Thais C Contente; Durvanei A Maria; Raul C Maranhão
Journal:  Int J Nanomedicine       Date:  2010-09-20

7.  LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.

Authors:  Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  Biomimetic, synthetic HDL nanostructures for lymphoma.

Authors:  Shuo Yang; Marina G Damiano; Heng Zhang; Sushant Tripathy; Andrea J Luthi; Jonathan S Rink; Andrey V Ugolkov; Amareshwar T K Singh; Sandeep S Dave; Leo I Gordon; C Shad Thaxton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

9.  Anticancer activity of the cholesterol exporter ABCA1 gene.

Authors:  Bradley Smith; Hartmut Land
Journal:  Cell Rep       Date:  2012-09-13       Impact factor: 9.423

10.  Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design.

Authors:  Tatiana Y Hargrove; Laura Friggeri; Zdzislaw Wawrzak; Suneethi Sivakumaran; Eugenia M Yazlovitskaya; Scott W Hiebert; F Peter Guengerich; Michael R Waterman; Galina I Lepesheva
Journal:  J Lipid Res       Date:  2016-06-16       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.